Skip to main content
Log in

Nonfunctional Pancreatic Neuroendocrine Tumors <2 cm on Preoperative Imaging are Associated with a Low Incidence of Nodal Metastasis and an Excellent Overall Survival

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Background

The optimal surgical management of small nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) remains controversial. We sought to identify (1) clinicopathologic factors associated with survival in NF-PNETs and (2) preoperative tumor characteristics that can be used to determine which lesions require resection and lymph node (LN) harvest.

Methods

The records of all 116 patients who underwent resection for NF-PNETs between 1989 and 2012 were reviewed retrospectively. Preoperative factors, operative data, pathology, surgical morbidity, and survival were analyzed.

Results

The overall 5- and 10-year survival rates were 83.9 and 72.8 %, respectively. Negative LNs (p = 0.005), G1 or G2 histology (p = 0.033), and age <60 years (p = 0.002) correlated with better survival on multivariate analysis. The 10-year survival rate was 86.6 % for LN-negative patients (n = 73) and 34.1 % for LN-positive patients (n = 32). Tumor size ≥2 cm on preoperative imaging predicted nodal positivity with a sensitivity of 93.8 %. Positive LNs were found in 38.5 % of tumors ≥2 cm compared to only 7.4 % of tumors <2 cm.

Conclusions

LN status, a marker of systemic disease, was a highly significant predictor of survival in this series. Tumor size on preoperative imaging was predictive of nodal disease. Thus, it is reasonable to consider parenchyma-sparing resection or even close observation for NF-PNETs <2 cm.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19(10):1727–33.

    Article  PubMed  CAS  Google Scholar 

  2. Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol. 2012;24(1):46–55.

    Article  PubMed  Google Scholar 

  3. Kulke M, Bendell J, Kvols L. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011;4(1):29.

    Article  PubMed  Google Scholar 

  4. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–92.

    Article  PubMed  CAS  Google Scholar 

  5. Kulke MH, Anthony LB, Bushnell DL, De Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL. NANETS treatment guidelines: well-differentiated tumors of the stomach and pancreas. Pancreas. 2010;39(6):735–52.

    Article  PubMed  Google Scholar 

  6. Jensen RT, Cadiot G, Brandi ML, De Herder WW, Kaltsas G, Komminoth P, Scoazec J-Y, Salazar R, Sauvanet A, Kianmanesh R. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98–119.

    Article  PubMed  CAS  Google Scholar 

  7. Falconi M, Bartsch DK, Eriksson B, Kloppel G, Lopes JM, O'Connor JM, Salazar R, Taal BG, Vullierme MP, O'Toole D. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95(2):120–34.

    Article  PubMed  CAS  Google Scholar 

  8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology neuroendocrine tumors. Version 2.2013. [Accessed Aug. 21, 2013]. Available from: http://www.nccn.org

  9. Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P, Scarpa A, Falconi M. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. 2011;150(1):75–82.

    Article  PubMed  Google Scholar 

  10. Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL, Levy MJ, Huebner M. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012;152(6):965–74.

    Article  PubMed  Google Scholar 

  11. Haynes AB, Deshpande V, Ingkakul T, Vageft P, Szymonifka J, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fernandez del Castillo C. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg. 2011;146(5):534–8.

    Article  PubMed  Google Scholar 

  12. Kim M, Choi D, Choi S. Surgical strategies for non-functioning pancreatic neuroendocrine tumors. Br J Surg. 2012;99(11):1562–8.

    Article  PubMed  CAS  Google Scholar 

  13. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115(4):741–51.

    Article  PubMed  Google Scholar 

  14. Gomez-Rivera F, Stewart AE, Arnoletti JP, Vickers S, Bland KI, Heslin MJ. Surgical treatment of pancreatic endocrine neoplasms. Am J Surg. 2007;193(4):460–5.

    Article  PubMed  Google Scholar 

  15. Zerbi A, Capitanio V, Boninsegna L, Pasquali C, Rindi G, Delle Fave G, Del Chiaro M, Casadei R, Falconi M. Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases. Langenbecks Arch Surg. 2011;396(3):313–21.

    Article  PubMed  Google Scholar 

  16. Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg. 2010;14(3):541–8.

    Article  PubMed  Google Scholar 

  17. Martin RC, Kooby DA, Weber SM, Merchant NB, Parikh AA, Cho CS, Ahmad SA, Kim HJ, Hawkins W, Scoggins CR. Analysis of 6,747 pancreatic neuroendocrine tumors for a proposed staging system. J Gastrointest Surg. 2011;15(1):175–83.

    Article  PubMed  Google Scholar 

  18. Klimstra D, Modlin I, Coppola D, Lloyd R, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–12.

    Article  PubMed  Google Scholar 

  19. Bosman FT, Carneiro F, Hruban RH. WHO classification of tumors of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010.

  20. Cherif R, Gaujoux S, Couvelard A, Dokmak S, Vuillerme MP, Ruszniewski P, Belghiti J, Sauvanet A. Parenchyma-sparing resections for pancreatic neuroendocrine tumors. J Gastrointest Surg. 2012;16(11):2045–55.

    Article  PubMed  Google Scholar 

  21. DiNorcia J, Lee MK, Reavey PL, Genkinger JM, Lee JA, Schrope BA, Chabot JA, Allendorf JD. One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques. J Gastrointest Surg. 2010;14(10):1536–46.

    Article  PubMed  Google Scholar 

  22. Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio V, Bassi C, Di Carlo V, Pederzoli P. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010;17(6):1621–7.

    Article  PubMed  Google Scholar 

  23. Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg. 2005;141:765–70.

    Article  Google Scholar 

  24. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247(3):490–500.

    Article  PubMed  Google Scholar 

  25. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23(6):824–33.

    Article  PubMed  CAS  Google Scholar 

  26. Krampitz GW, Norton JA, Poultsides GA, Visser BC, Sun L, Jensen RT. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg. 2012;147(9):820–7.

    Article  PubMed  Google Scholar 

  27. Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012;41(6):840–4.

    Article  PubMed  Google Scholar 

  28. Cauley CE, Pitt HA, Ziegler KM, Nakeeb A, Schmidt CM, Zyromski NJ, House MG, Lillemoe KD. Pancreatic enucleation: improved outcomes compared to resection. J Gastrointest Surg. 2012;16(7):1347–53.

    Article  PubMed  CAS  Google Scholar 

  29. Hackert T, Hinz U, Fritz S, Strobel O, Schneider L, Hartwig W, Büchler MW, Werner J. Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections. Langenbecks Arch Surg. 2011;396(8):1197–203.

    Article  PubMed  Google Scholar 

  30. Pitt SC, Pitt HA, Baker MS, Christians K, Touzios JG, Kiely JM, Weber SM, Wilson SD, Howard TJ, Talamonti MS, Rikkers LF. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg. 2009;13(9):1692–8.

    Article  PubMed  Google Scholar 

  31. Chatzipantelis P, Konstantinou P, Kaklamanos M, Apostolou G, Salla C. The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology. Cancer. 2009;117(3):211–6.

    PubMed  Google Scholar 

  32. Larghi A, Verna EC, Stavropoulos SN, Rotterdam H, Lightdale CJ, Stevens PD. EUS-guided trucut needle biopsies in patients with solid pancreatic masses: a prospective study. Gastrointest Endosc. 2004;59(2):185–90.

    Article  PubMed  Google Scholar 

  33. Matsubara J, Okusaka T, Morizane C, Ikeda M, Ueno H. Ultrasound-guided percutaneous pancreatic tumor biopsy in pancreatic cancer: a comparison with metastatic liver tumor biopsy, including sensitivity, specificity, and complications. J Gastroenterol. 2008;43(3):225–32.

    Article  PubMed  Google Scholar 

  34. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35(6):853–60.

    Article  PubMed  Google Scholar 

  35. Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O, Colnot N, Paradis V, Belghiti J, Bedossa P, Ruszniewski P. Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol. 2009;22(2):273–81.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Paul A. Toste or Timothy R. Donahue.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toste, P.A., Kadera, B.E., Tatishchev, S.F. et al. Nonfunctional Pancreatic Neuroendocrine Tumors <2 cm on Preoperative Imaging are Associated with a Low Incidence of Nodal Metastasis and an Excellent Overall Survival. J Gastrointest Surg 17, 2105–2113 (2013). https://doi.org/10.1007/s11605-013-2360-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-013-2360-9

Keywords

Navigation